Posted by Michael Wonder on 27 Apr 2017
NICE recommends Amgen's Blincyto (blinatumomab) for adults with relapsed or refractory Philadelphia chromosome negative B-precursor acute lymphoblastic leukaemia
27 April 2017 - FAD reinforces significant need for innovative treatment options for patients with relapsed or refractory acute lymphoblastic leukaemia.
Today the National Institute for Health and Care Excellence has published its final appraisal determination recommending Blincyto (blinatumomab) as an option for treating adults with Philadelphia-chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia, on the basis of the discount agreed in the patient access scheme. NICE reviewed the data available on the clinical and cost-effectiveness of blinatumomab.
Having considered evidence on the nature of the disease and the value placed on the benefits of blinatumomab by people with the condition, those who represent them, and clinical experts, NICE concluded that it is a cost-effective use of NHS resources under the end-of-life criteria.
